BMI View: Although the Danish pharmaceutical market will post another year of weak growth for 2016, we
expect the sector to slowly pick up pace over the next five years. Medicine sales will be driven by an ageing
population and rising chronic diseases, creating a fa ..."
BMI View: Although Denmark has a relatively small pharmaceutical market compared to its Western
European counterparts, its high per capita spending makes it an attractive market for innovative
drugmakers. An aging population and sizable non-communicable disease burden ..."
BMI View: Limited by its population size, Denmark has a relatively small pharmaceutical market
compared to its Western European counterparts. We believe that pharmaceutical market growth will
continue in 2016 in local currency terms, especially as economic conditions ..."
BMI View: Despite Denmark's relatively small pharmaceutical market, which is restricted by the
government's tough fiscal policies, we believe Denmark will remain an attractive market for drugmakers.
The country's ageing population and high per capita spending will ens ..."
BMI View: In comparison to other Western European markets, Denmark's pharmaceutical industry is
relatively small. However, BMI views Denmark as a highly attractive market for multinational drugmakers
as a result of the country's stringent regulations, business transpa ..."
BMI View: Improving economic conditions in Europe will ensure the continued strong growth of
Denmark's economy. This will help offset the negative impact of drug patent expiration and price reductions
in the medium-term. The country's aging population and relatively h ..."
BMI View: Our outlook for Denmark's pharmaceutical industry is relatively optimistic going into 2015 as
we expect the country's small pharmaceutical market to return to growth for the first time since 2009. We
maintain our view that Denmark is an attractive market for drugmaker ..."
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Denmark". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in ..."
BMI View: Like many other Western European countries, Denmark's expanding elderly population will
ensure that demand for quality healthcare remains high and will be a key driving factor for its wellestablished,
albeit relatively small, pharmaceutical market. The robus ..."
BMI View: Although Denmark's pharmaceutical market is relatively small compared to other Western
European countries, the demand for high quality healthcare will remain elevated by an increasing and
ageing population. This demand could provide opportunities for private ..."